Sarka Blahutova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sarka Blahutova has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Zuzana Cermakova
Blood Center, University Hospital Ostrava, Ostrava, Czech Republic
3 shared publications - Aleš Chrdle
University of South Bohemia in Ceske Budejovice, Faculty of Science, Department of Medical Biology, Ceske Budejovice, Czech Republic
1 shared publication Dana Galuszkova
Department of Transfusion Medicine University Hospital Olomouc
1 shared publication- David Řezáč
Metabolic Intensive Care Unit, Transplant Centre Institute for Clinical and Experimental Medicine (IKEM) Prague Czech Republic
1 shared publication - Dominik Kutac
Department of Hematology and Blood Transfusion Military University Hospital Prague Czech Republic
1 shared publication - Edgar Faber
Department of Hemato‐Oncology, Faculty of Medicine and Dentistry Palacký University Olomouc and University Hospital Olomouc Olomouc Czech Republic
1 shared publication
Latest Publications
- 15 September 2023
- Published by Care Comm in Transfuze a hematologie dnes
- Vol. 29 (3)
Report on the program of the use of convalescent plasma in the treatment of patients with COVID-19 in the Czech Republic and the results of the national multicentre study RESCOVID-19
The biggest source of information for doctors – proLékaře.cz
- 15 September 2023
- Published by Care Comm in Transfuze a hematologie dnes
- Vol. 29 (3)
Report on the program of the use of convalescent plasma in the treatment of patients with COVID-19 in the Czech Republic and the results of the national multicentre study RESCOVID-19
The biggest source of information for doctors – proLékaře.cz
- 1 November 2019
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 26 (4) , 299-303
Granulocyte transfusions collected after steroid priming for severe infections during neutropenia: A single center experience
- 1 November 2019
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 26 (4) , 299-303
Granulocyte transfusions collected after steroid priming for severe infections during neutropenia: A single center experience
- 5 November 2018
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 34 (1) , 13-20
ADAMTS13 kinetics after therapeutic plasma exchange and plasma infusion in patients with Upshaw‐Schulman syndrome
Background: Hereditary thrombotic thrombocytopenic purpura, also called Upshaw‐Schulman syndrome (USS), is a rare disease caused by genetic mutations in the ADAMTS13 gene, which severely decrease the activity of ADAMTS13, a metalloprotease that cleaves von Willebrand factor multimers (VWF). Genotypically identical patients can show great phenotypic diversity.Objectives: Comparison of selected laboratory parameters and ADAMTS13 pharmacokinetics among patients with USS was performed.Patients/methods: Six patients with USS on prophylactic plasma therapy have been reviewed, retrospectively. Blood counts, lactate dehydrogenase (LDH), and ADAMTS13 activity at various time‐points before and after different treatment cycles were evaluated.Results: ADAMTS13 recovery and pharmacokinetics were affected by treatment modality, and also reflected the patients' comorbidities and their current physiological and clinical condition.Conclusions: Our present findings support a multifactorial contribution to treatment efficacy, and confirm the importance of adaptability and individualization of USS therapy. Therapeutic plasma exchange even in hereditary TTP is an option that can in some patients prolong intervals between plasma administration.
- 5 November 2018
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 34 (1) , 13-20
ADAMTS13 kinetics after therapeutic plasma exchange and plasma infusion in patients with Upshaw‐Schulman syndrome
Background: Hereditary thrombotic thrombocytopenic purpura, also called Upshaw‐Schulman syndrome (USS), is a rare disease caused by genetic mutations in the ADAMTS13 gene, which severely decrease the activity of ADAMTS13, a metalloprotease that cleaves von Willebrand factor multimers (VWF). Genotypically identical patients can show great phenotypic diversity.Objectives: Comparison of selected laboratory parameters and ADAMTS13 pharmacokinetics among patients with USS was performed.Patients/methods: Six patients with USS on prophylactic plasma therapy have been reviewed, retrospectively. Blood counts, lactate dehydrogenase (LDH), and ADAMTS13 activity at various time‐points before and after different treatment cycles were evaluated.Results: ADAMTS13 recovery and pharmacokinetics were affected by treatment modality, and also reflected the patients' comorbidities and their current physiological and clinical condition.Conclusions: Our present findings support a multifactorial contribution to treatment efficacy, and confirm the importance of adaptability and individualization of USS therapy. Therapeutic plasma exchange even in hereditary TTP is an option that can in some patients prolong intervals between plasma administration.
- Open Access
- 23 June 2014
- Published by Palacky University Olomouc in Biomedical Papers
- Vol. 158 (2) , 309-312
Procedure for granulocyte collection performed at the Blood Centre of the Faculty Hospital Ostrava
Background: Granulocyte apheresis is a safe and effective method for granulocyte collection. We present a five year experience (2006-2010) of the Blood Center, Faculty Hospital Ostrava, Czech Republic. Donor granulocyte transfusion is one treat...
- 23 June 2014
- Published by Palacky University Olomouc in Biomedical Papers
- Vol. 158 (2) , 309-312
Open AccessProcedure for granulocyte collection performed at the Blood Centre of the Faculty Hospital Ostrava
Background: Granulocyte apheresis is a safe and effective method for granulocyte collection. We present a five year experience (2006-2010) of the Blood Center, Faculty Hospital Ostrava, Czech Republic. Donor granulocyte transfusion is one treat...
- Open Access
- 1 January 2012
- Published by Charles University in Prague, Karolinum Press in Prague Medical Report
- Vol. 113 (4) , 294-298
Transfusion-related Acute Lung Injury: Report of Two Cases
Transfusion-related acute lung injury (TRALI) is a severe life-threatening complication of blood transfusion, characterized by acute lung injury developing within 2–6 h of transfusion. However, TRALI is difficult to diagnose, and the initial report or suspicion of TRALI depends on close collaboration between clinical departments and transfusion centres. A total of 17 adverse post-transfusion reactions were reported to the Blood Centre of the University Hospital Ostrava as suspected TRALI between 2005 and 2010. We report two cases of serious TRALI with different pathogenetic mechanisms.
- 1 January 2012
- Published by Charles University in Prague, Karolinum Press in Prague Medical Report
- Vol. 113 (4) , 294-298
Open AccessTransfusion-related Acute Lung Injury: Report of Two Cases
Transfusion-related acute lung injury (TRALI) is a severe life-threatening complication of blood transfusion, characterized by acute lung injury developing within 2–6 h of transfusion. However, TRALI is difficult to diagnose, and the initial report or suspicion of TRALI depends on close collaboration between clinical departments and transfusion centres. A total of 17 adverse post-transfusion reactions were reported to the Blood Centre of the University Hospital Ostrava as suspected TRALI between 2005 and 2010. We report two cases of serious TRALI with different pathogenetic mechanisms.